Glenmark Pharma reports positive data in Phase 2a study of GBR 830 News News / News 7 years ago 570 Views comments Glenmark Pharmaceuticals announced positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, in atopic dermat... Read more
News Market Live: Sensex opens 100 pts higher to reclaim 32K, Nifty nears 10,050 News / News - 7 years ago
Comments